axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
questa è una grande notizia
per igxt
ha bisogno di tempo
per prendere attenzione
sottovalutato alla grande
igxt
- Creatore Discussione axelvento
- Data di inizio
-
Due nuove obbligazioni Societe Generale, in Euro e in Dollaro USA
Societe Generale porta sul segmento Bond-X (EuroTLX) di Borsa Italiana due obbligazioni, una in EUR e una in USD, a tasso fisso decrescente con durata massima di 15 anni e possibilità di rimborso anticipato annuale a discrezione dell’Emittente.
Per continuare a leggere visita questo LINK
questa è una grande notizia
per igxt
ha bisogno di tempo
per prendere attenzione
sottovalutato alla grande
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
Per la versione cinematografica sul mercato gli unici sono BDSI e IGXT - IGXT cmq. ha sicuramente i brevetti migliori. BDSI ha un marketcap di $ 199 M e quasi nulla in cantiere rispetto a IGXT con una capitalizzazione di mercato ridicolo di $ 28 M e un Mega pipeline di prodotti. Per me otc frena l'azienda, che ne pensate? perché non decolla?
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
questa è la data che fa scattare il tutto!
announced that the U.S. Food and Drug Administration ("FDA") has assigned a Prescription Drug User Fee Act ("PDUFA") action date of February 3, 2014 for the review of the Company's New Drug Application ("NDA") for the marketing approval of IntelGenx' Anti-Migraine VersaFilm(TM) oral film product.
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
NDA for Anti-Migraine VersaFilm™ Oral Film Product:
On June 18, 2013 we announced that the FDA has assigned a Prescription Drug User Fee Act ("PDUFA") action date of February 3, 2014 for the review of the our New Drug Application ("NDA") for the marketing approval of our anti-migraine VersaFilm™ oral film product. We had previously announced that, together with our co-development partner RedHill Biopharma Ltd ("RedHill"), we had submitted a 505(b)(2) NDA to the FDA for a novel, oral thin-film formulation, based on our proprietary VersaFilm™ technology containing Rizatriptan, the active drug in Merck & Co ("Merck") Maxalt-MLT® orally disintegrating tablets. According to Merck's most recent annual report, sales of Maxalt® were $638 million in 2012. The FDA confirmed that our application is sufficiently complete to permit a substantive review in accordance with the FDA's "standard" classification process.
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
news:
IntelGenx Announces Public Offering of $3,500,000 of Common Stock
SAINT LAURENT, Quebec, Dec. 12, 2013 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (IGXT) (IGX.V) ("IntelGenx"), a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm(TM) technology, as well as oral controlled-release products, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $3.5 million of securities in a registered public offering. IntelGenx has agreed to sell to institutional investors an aggregate of 7,920,346 shares of its common stock at $0.4419 per share. Additionally, investors will receive warrants to purchase up to 7,920,346 shares of common stock at an exercise price of $0.5646 per share for a term of five years.
The gross proceeds of the offering are expected to be approximately $3.5 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by IntelGenx, are expected to be approximately $3.14 million.
IntelGenx intends to use proceeds from the offering for capital investment in VersaFilm(TM) manufacturing equipment, manufacturing facility improvements and general corporate purposes.
H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction.
The offering is expected to close on or about December 16, 2013, subject to customary closing conditions.
The securities described above are being offered by IntelGenx Technologies Corp. pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from IntelGenx and at the SEC's website at U.S. Securities and Exchange Commission | Homepage or by request at H.C. Wainwright & Co., LLC at placements@hcwco.com.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of by IntelGenx Technologies Corp.'s common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, bipolar disorder, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at IntelGenX.
IntelGenx Announces Public Offering of $3,500,000 of Common Stock
SAINT LAURENT, Quebec, Dec. 12, 2013 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (IGXT) (IGX.V) ("IntelGenx"), a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm(TM) technology, as well as oral controlled-release products, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $3.5 million of securities in a registered public offering. IntelGenx has agreed to sell to institutional investors an aggregate of 7,920,346 shares of its common stock at $0.4419 per share. Additionally, investors will receive warrants to purchase up to 7,920,346 shares of common stock at an exercise price of $0.5646 per share for a term of five years.
The gross proceeds of the offering are expected to be approximately $3.5 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by IntelGenx, are expected to be approximately $3.14 million.
IntelGenx intends to use proceeds from the offering for capital investment in VersaFilm(TM) manufacturing equipment, manufacturing facility improvements and general corporate purposes.
H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction.
The offering is expected to close on or about December 16, 2013, subject to customary closing conditions.
The securities described above are being offered by IntelGenx Technologies Corp. pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from IntelGenx and at the SEC's website at U.S. Securities and Exchange Commission | Homepage or by request at H.C. Wainwright & Co., LLC at placements@hcwco.com.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of by IntelGenx Technologies Corp.'s common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, bipolar disorder, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at IntelGenX.
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
PDUFA Feb 4, for VersaFilm FDA Calendar
sta per cominciare la speculazione....
alert$$$$$$$$$$$
è pronta!
